Hemington Wealth Management’s Sage Therapeutics SAGE Stock Holding History

Hemington Wealth Management’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-8	Closed	–	–	1752
2024 Q3	$0	Buy	+8	New	+$73	﹤0.01%	1710

Other funds holding SAGE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Hemington Wealth Management's SAGE Position: Q4 2024 in Review

Hemington Wealth Management sold out of Sage Therapeutics (SAGE) in Q4 2024, closing a stake of 8 shares.

Hemington Wealth Management first reported a position in SAGE in Q3 2024 and held it in 1 quarter. The position peaked at $0 in Q3 2024. 177 funds tracked by Wall St. Rank hold SAGE as of Q4 2024.

Hemington Wealth Management reported no remaining Sage Therapeutics position as of Q4 2024 after selling out during the quarter.
Hemington Wealth Management sold 8 Sage Therapeutics shares in Q4 2024.
Hemington Wealth Management first reported a position in Sage Therapeutics in Q3 2024 and held it in 1 quarter.
Hemington Wealth Management's Sage Therapeutics position peaked at $0 in Q3 2024.
177 funds tracked by Wall St. Rank held Sage Therapeutics as of Q4 2024.

Based on Hemington Wealth Management's 13F filing for Q4 2024, filed 29 Jan 2025.